269 related articles for article (PubMed ID: 11264450)
1. Tumor cell death induced by topoisomerase-targeting drugs.
Li TK; Liu LF
Annu Rev Pharmacol Toxicol; 2001; 41():53-77. PubMed ID: 11264450
[TBL] [Abstract][Full Text] [Related]
2. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
3. Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.
Arimondo PB; Hélène C
Curr Med Chem Anticancer Agents; 2001 Nov; 1(3):219-35. PubMed ID: 12678755
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of DNA topoisomerase inhibitors.
Binaschi M; Zunino F; Capranico G
Stem Cells; 1995 Jul; 13(4):369-79. PubMed ID: 7549896
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
Lotito L; Ferri F; Russo A; Capranico G
Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
Nitiss JL
Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
[TBL] [Abstract][Full Text] [Related]
9. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.
Ganguly A; Das B; Roy A; Sen N; Dasgupta SB; Mukhopadhayay S; Majumder HK
Cancer Res; 2007 Dec; 67(24):11848-58. PubMed ID: 18089815
[TBL] [Abstract][Full Text] [Related]
10. Diversity of DNA topoisomerases I and inhibitors.
Pommier Y
Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
[TBL] [Abstract][Full Text] [Related]
11. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
Capranico G; Binaschi M
Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase I poisons and suppressors as anticancer drugs.
Bailly C
Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
[TBL] [Abstract][Full Text] [Related]
13. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
14. [DNA topoisomerase inhibitor].
Hino M; Niitani H
Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
[TBL] [Abstract][Full Text] [Related]
15. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs.
Degrassi F; Fiore M; Palitti F
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):317-25. PubMed ID: 15281904
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase inhibitors as anticancer agents: a patent update.
Khadka DB; Cho WJ
Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
[TBL] [Abstract][Full Text] [Related]
18. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
19. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
Gatto B; Capranico G; Palumbo M
Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
[TBL] [Abstract][Full Text] [Related]
20. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
